SANJAY PAL

About

Dr. Sanjay Pal is a cancer biologist specializing in biomaterials and immunotherapy. He completed his undergraduate studies at the University of Allahabad, India, and obtained his Ph.D. in Cancer Biology from the Regional Center for Biotechnology (RCB), India. His doctoral research focused on investigating the biomedical applications of low molecular weight hydrogels (LMWH), for the treatment of cancer and infectious diseases. Currently, Dr. Pal is a postdoctoral fellow in the Cancer Innovation Laboratory at the National Cancer Institute (NCI) in Frederick, working under the mentorship of Dr. Matthew Wolf. His research explores the use of decellularized extracellular matrix (ECM) scaffolds in cancer vaccine immunotherapy.

Employment

• National Cancer Institute Visiting Fellow
  2021 - Present
• Regional Centre for Biotechnology Ph.D
  2014 - 2021

Education

• Regional Centre for Biotechnology Ph.D.
  2014 - 2021
• University of Allahabad Master of Science (M.Sc)
  2012 - 2014
• University of Delhi Bachelor of Science (B.S.)
  2009 - 2012

Projects & Funding

Projects & funding information is unavailable.

Publications (24)

• PEGylation strategies for enhanced nanoparticle delivery to tumor associated immune cells
  2025 DOI: 10.1101/2025.07.23.666401
  +Save
• Extracellular Matrix Scaffold-Assisted Tumor Vaccines Induce Tumor Regression and Long-Term Immune Memory
  2025 DOI: 10.52843/cassyni.ldtgqx
  +Save
• Inflammatory Agonists Modulate the Host Response to Type 2 ECM scaffold Immune Environment and Long-Term Remodeling After Severe Traumatic Injury
  2025 DOI: 10.1101/2025.11.09.687444
  +Save
• Extracellular Matrix Scaffold‐Assisted Tumor Vaccines Induce Tumor Regression and Long‐Term Immune Memory
  Advanced Materials 2024 DOI: 10.1002/adma.202309843
  +Save
• Extracellular matrix scaffold-assisted tumor vaccines induce tumor regression and long-term immune memory
  2023 DOI: 10.1101/2023.09.12.557449
  +Save
• A localized hydrogel-mediated chemotherapy causes immunogenic cell death via activation of ceramide-mediated unfolded protein response
  Science Advances 2023 DOI: 10.1126/sciadv.adf2746
  +Save
• Targeting Vancomycin-ResistantEnterococci(VRE) Infections and Van Operon-Mediated Drug Resistance Using Dimeric Cholic Acid–Peptide Conjugates
  Journal of Medicinal Chemistry 2022 DOI: 10.1021/acs.jmedchem.2c01293
  +Save
• Self-assembled supramolecular nanomicelles from a bile acid–docetaxel conjugate are highly tolerable with improved therapeutic efficacy
  Biomaterials Science 2021 DOI: 10.1039/D1BM00031D
  +Save
• A hydrogel-based implantable multidrug antitubercular formulation outperforms oral delivery
  Nanoscale 2021 DOI: 10.1039/D0NR08806D
  +Save
• Bile Acid Tethered Docetaxel‐Based Nanomicelles Mitigate Tumor Progression through Epigenetic Changes
  Angewandte Chemie International Edition 2021 DOI: 10.1002/anie.202015173
  +Save